Bank of Montreal Can Has $670,000 Holdings in Genmab A/S (NASDAQ:GMAB)

Bank of Montreal Can lessened its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 57.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,109 shares of the company's stock after selling 43,710 shares during the period. Bank of Montreal Can's holdings in Genmab A/S were worth $670,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. AIMZ Investment Advisors LLC bought a new stake in shares of Genmab A/S during the fourth quarter worth $3,525,000. HighTower Advisors LLC bought a new stake in Genmab A/S during the 3rd quarter worth about $273,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Genmab A/S by 229.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company's stock valued at $1,033,000 after purchasing an additional 34,652 shares during the period. Blue Trust Inc. boosted its stake in shares of Genmab A/S by 33.4% in the 4th quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock valued at $120,000 after purchasing an additional 1,442 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Genmab A/S during the 4th quarter worth approximately $2,463,000. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Stock Down 0.1 %

Shares of NASDAQ:GMAB traded down $0.02 during mid-day trading on Friday, reaching $20.52. 257,353 shares of the stock were exchanged, compared to its average volume of 1,044,945. The company has a market cap of $13.58 billion, a P/E ratio of 11.79, a P/E/G ratio of 2.65 and a beta of 1.07. The stock's 50 day simple moving average is $20.50 and its 200-day simple moving average is $21.08. Genmab A/S has a one year low of $17.24 and a one year high of $30.41.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the stock. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and set a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Finally, Truist Financial dropped their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $39.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.